{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T21:15:58Z","timestamp":1793740558306,"version":"4.6.1"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Heart Fail Rev"],"DOI":"10.1007\/s10741-024-10444-4","type":"journal-article","created":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T20:21:00Z","timestamp":1727814060000},"page":"69-73","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Contextualizing the results of HELIOS-B in the broader landscape of clinical trials for the treatment of transthyretin cardiac amyloidosis"],"prefix":"10.1007","volume":"30","author":[{"given":"Andrew A.","family":"Girard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brett W.","family":"Sperry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,1]]},"reference":[{"key":"10444_CR1","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1716153","volume":"379","author":"D Adams","year":"2018","unstructured":"Adams D, Gonzalez-Duarte A, O\u2019Riordan WD et al (2018) Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N Engl J Med 379:11\u201321. https:\/\/doi.org\/10.1056\/NEJMoa1716153","journal-title":"N Engl J Med"},{"key":"10444_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/13506129.2022.2091985","volume":"30","author":"D Adams","year":"2023","unstructured":"Adams D, Tournev IL, Taylor MS et al (2023) Efficacy and safety of vutrisiran for patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: a randomized clinical trial. Amyloid 30:1\u20139. https:\/\/doi.org\/10.1080\/13506129.2022.2091985","journal-title":"Amyloid"},{"key":"10444_CR3","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1038\/35078107","volume":"411","author":"SM Elbashir","year":"2001","unstructured":"Elbashir SM, Harborth J, Lendeckel W et al (2001) Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 411:494\u2013498. https:\/\/doi.org\/10.1038\/35078107","journal-title":"Nature"},{"key":"10444_CR4","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1038\/35888","volume":"391","author":"A Fire","year":"1998","unstructured":"Fire A, Xu S, Montgomery MK et al (1998) Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 391:806\u2013811. https:\/\/doi.org\/10.1038\/35888","journal-title":"Nature"},{"key":"10444_CR5","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1002\/ejhf.3138","volume":"26","author":"P Garcia-Pavia","year":"2024","unstructured":"Garcia-Pavia P, Grogan M, Kale P et al (2024) Impact of vutrisiran on exploratory cardiac parameters in hereditary transthyretin-mediated amyloidosis with polyneuropathy. Eur J Heart Fail 26:397\u2013410. https:\/\/doi.org\/10.1002\/ejhf.3138","journal-title":"Eur J Heart Fail"},{"key":"10444_CR6","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1056\/NEJMoa2107454","volume":"385","author":"JD Gillmore","year":"2021","unstructured":"Gillmore JD, Gane E, Taubel J et al (2021) CRISPR-Cas9 in vivo gene editing for transthyretin amyloidosis. N Engl J Med 385:493\u2013502. https:\/\/doi.org\/10.1056\/NEJMoa2107454","journal-title":"N Engl J Med"},{"key":"10444_CR7","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1056\/NEJMoa2305434","volume":"390","author":"JD Gillmore","year":"2024","unstructured":"Gillmore JD, Judge DP, Cappelli F et al (2024) Efficacy and safety of acoramidis in transthyretin amyloid cardiomyopathy. N Engl J Med 390:132\u2013142. https:\/\/doi.org\/10.1056\/NEJMoa2305434","journal-title":"N Engl J Med"},{"key":"10444_CR8","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1002\/cpt.1974","volume":"109","author":"BA Habtemariam","year":"2021","unstructured":"Habtemariam BA, Karsten V, Attarwala H et al (2021) Single-dose pharmacokinetics and pharmacodynamics of transthyretin targeting N-acetylgalactosamine\u2013small interfering ribonucleic acid conjugate, vutrisiran, in healthy subjects. Clin Pharmacol Ther 109:372\u2013382. https:\/\/doi.org\/10.1002\/cpt.1974","journal-title":"Clin Pharmacol Ther"},{"key":"10444_CR9","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1007\/PL00000791","volume":"58","author":"JA Hamilton","year":"2001","unstructured":"Hamilton JA, Benson MD (2001) Transthyretin: a review from a structural perspective. CMLS, Cell Mol Life Sci 58:1491\u20131521. https:\/\/doi.org\/10.1007\/PL00000791","journal-title":"CMLS, Cell Mol Life Sci"},{"key":"10444_CR10","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","volume":"379","author":"MS Maurer","year":"2018","unstructured":"Maurer MS, Schwartz JH, Gundapaneni B et al (2018) Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N Engl J Med 379:1007\u20131016. https:\/\/doi.org\/10.1056\/NEJMoa1805689","journal-title":"N Engl J Med"},{"key":"10444_CR11","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1056\/NEJMoa2300757","volume":"389","author":"MS Maurer","year":"2023","unstructured":"Maurer MS, Kale P, Fontana M et al (2023) Patisiran treatment in patients with transthyretin cardiac amyloidosis. N Engl J Med 389:1553\u20131565. https:\/\/doi.org\/10.1056\/NEJMoa2300757","journal-title":"N Engl J Med"},{"key":"10444_CR12","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1038\/s41573-019-0017-4","volume":"18","author":"RL Setten","year":"2019","unstructured":"Setten RL, Rossi JJ, Han S (2019) The current state and future directions of RNAi-based therapeutics. Nat Rev Drug Discov 18:421\u2013446. https:\/\/doi.org\/10.1038\/s41573-019-0017-4","journal-title":"Nat Rev Drug Discov"},{"key":"10444_CR13","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1136\/heartjnl-2016-309914","volume":"103","author":"BW Sperry","year":"2017","unstructured":"Sperry BW, Tang WHW (2017) Amyloid heart disease: genetics translated into disease-modifying therapy. Heart 103:812\u2013817. https:\/\/doi.org\/10.1136\/heartjnl-2016-309914","journal-title":"Heart"},{"key":"10444_CR14","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1001\/jamacardio.2022.5251","volume":"8","author":"BW Sperry","year":"2023","unstructured":"Sperry BW, Hanna M, Maurer MS et al (2023) Association of tafamidis with health status in patients with ATTR cardiac amyloidosis: a post hoc analysis of the ATTR-ACT randomized clinical trial. JAMA Cardiol 8:275\u2013280. https:\/\/doi.org\/10.1001\/jamacardio.2022.5251","journal-title":"JAMA Cardiol"},{"key":"10444_CR15","doi-asserted-by":"publisher","unstructured":"Fontana M, Berk JL, Gillmore JD, et al. (2024) Vutrisiran in Patients with transthyretin amyloidosis with cardiomyopathy. N Engl J Med NEJMoa2409134. https:\/\/doi.org\/10.1056\/NEJMoa2409134","DOI":"10.1056\/NEJMoa2409134"},{"key":"10444_CR16","unstructured":"Office of the FDA Commissioner (2020) FDA approves first-of-its kind targeted RNA-based therapy to treat a rare disease. In: FDA. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-its-kind-targeted-rna-based-therapy-treat-rare-disease. Accessed 24 Aug 2024"},{"key":"10444_CR17","doi-asserted-by":"publisher","unstructured":"Sperry BW, Sultan MB, Gundapaneni B, et al. (2024) Effect of tafamidis on renal function in patients with transthyretin amyloid cardiomyopathy in ATTR-ACT. JACC: CardioOncology 6:300\u2013306. https:\/\/doi.org\/10.1016\/j.jaccao.2024.02.007","DOI":"10.1016\/j.jaccao.2024.02.007"}],"container-title":["Heart Failure Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10741-024-10444-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10741-024-10444-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10741-024-10444-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,14]],"date-time":"2024-12-14T07:08:32Z","timestamp":1734160112000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10741-024-10444-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,1]]},"references-count":17,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,1]]}},"alternative-id":["10444"],"URL":"https:\/\/doi.org\/10.1007\/s10741-024-10444-4","relation":{},"ISSN":["1573-7322"],"issn-type":[{"value":"1573-7322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,1]]},"assertion":[{"value":"26 September 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 October 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"BWS consults for Alnylam, BridgeBio, AstraZeneca and is a speaker for Pfizer and AstraZeneca.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}